Log in to search using one of your social media accounts:

 

Roche reports strong sales growth in the first nine months of 2017
Group sales rose 5% to CHF 39.4 billion. Sales in the Pharmaceuticals Division increased 5% to CHF 30.6 billion. (Source: Roche Investor Update)
Source: Roche Investor Update - October 19, 2017 Category: Pharmaceuticals Source Type: news

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms of multiple sclerosis (MS) will be presented during the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Me eting in Paris, France, 25 to 28 October. (Source: Roche Investor Update)
Source: Roche Investor Update - October 16, 2017 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC
Roche announced today that the European Union ’s (EU) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Alecensa® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCL C). (Source: Roche Investor Update)
Source: Roche Investor Update - October 13, 2017 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche's 9 Months Sales 2017 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2017 prior to the opening of the Swiss Stock Exchange on Thursday October 19th, 2017. (Source: Roche Investor Update)
Source: Roche Investor Update - October 12, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus
Roche announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the cobas ® Zika test for use on the cobas 6800/8800 Systems. (Source: Roche Investor Update)
Source: Roche Investor Update - October 6, 2017 Category: Pharmaceuticals Source Type: news

Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams
Roche, today announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, or multi-disciplinary team meetings. (Source: Roche Investor Update)
Source: Roche Investor Update - October 3, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review for Roche ’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC). The FDA is exp ected to make a decision on approval by 28 January 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - September 29, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis
Roche announced today that the Swiss agency for the authorisation and supervision of therapeutic products (Swissmedic) has granted authorisation of OCREVUS ® (ocrelizumab) for the treatment of adult patients with active relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). (Source: Roche Investor Update)
Source: Roche Investor Update - September 28, 2017 Category: Pharmaceuticals Source Type: news

Roche receives EU approval of TECENTRIQ ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Roche today announced that the European Commission (EC) has granted a marketing authorisation for TECENTRIQ (atezolizumab) as a monotherapy for the treatment of people with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy regardless of PD-L1 status. (Source: Roche Investor Update)
Source: Roche Investor Update - September 22, 2017 Category: Pharmaceuticals Source Type: news

Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma
Roche announced today that the European Commission has approved Gazyvaro ® (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people achieving a response, as a new treatment for previously untreated advanced follicular lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - September 22, 2017 Category: Pharmaceuticals Source Type: news

Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche announced today that the European Commission (EC) has approved Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. Actemra/RoActemra is the first therapy approved for the treatment of GCA in Europe. (Source: Roche Investor Update)
Source: Roche Investor Update - September 22, 2017 Category: Pharmaceuticals Source Type: news

Invitation to Roche's 9 Months Sales 2017 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2017 prior to the opening of the Swiss Stock Exchange on Thursday October 19th, 2017. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2017 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2017 Category: Pharmaceuticals Source Type: news

TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement
Roche: Based on emerging safety data from clinical trials evaluating pembrolizumab in combination with either lenalidomide or pomalidomide in multiple myeloma, the FDA has requested that a Phase Ib and a Phase Ib/II TECENTRIQ study be placed on partial clinical hold. (Source: Roche Investor Update)
Source: Roche Investor Update - September 15, 2017 Category: Pharmaceuticals Source Type: news

Results of a six-month study combining Roche ’s Esbriet with nintedanib in patients with IPF presented at ERS
Roche today announced results of a six month study combining Esbriet (pirfenidone) and nintedanib treatment, showing a similar safety profile for the combination treatment to that expected for each treatment alone. (Source: Roche Investor Update)
Source: Roche Investor Update - September 13, 2017 Category: Pharmaceuticals Source Type: news

Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma
Roche today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf ® (vemurafenib) in the adjuvant (after surgery) treatment of people with completely resected, BRAF V600 mutation-positive melanoma. (Source: Roche Investor Update)
Source: Roche Investor Update - September 11, 2017 Category: Pharmaceuticals Source Type: news

Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration
Roche today announced that the primary endpoint has not been met in Spectri, the first of two phase III studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). (Source: Roche Investor Update)
Source: Roche Investor Update - September 8, 2017 Category: Pharmaceuticals Source Type: news

Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress
Roche announced today that the first data on a novel blood-based assay, co-developed with Foundation Medicine (NASDAQ: FMI), will be presented during the European Society for Medical Oncology (ESMO) Congress from 8-12 September 2017 in Madrid, Spain. (Source: Roche Investor Update)
Source: Roche Investor Update - September 8, 2017 Category: Pharmaceuticals Source Type: news

Roche ranked again the most sustainable healthcare company in the Dow Jones Sustainability Indices
For the ninth consecutive year, Roche has been recognised as Group Leader in sustainability within the Pharmaceuticals, Biotechnology& Life Sciences Industry index of the Dow Jones Sustainability Indices (DJSI). (Source: Roche Investor Update)
Source: Roche Investor Update - September 6, 2017 Category: Pharmaceuticals Source Type: news

Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Roche today announced results from the global phase III ALUR study showing that Alecensa ® significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by 85% compared to chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), who had progressed following treatment with platinum-based chemothe rapy and crizotinib (hazard ratio [HR]=0.15, 95% CI: 0.08-0.29, p (Source: Roche Investor Update)
Source: Roche Investor Update - September 6, 2017 Category: Pharmaceuticals Source Type: news

Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress
Roche today announced that new results from a number of studies across 18 approved and investigational medicines will be presented during the European Society for Medical Oncology (ESMO) Congress from 8-12 September in Madrid, Spain. (Source: Roche Investor Update)
Source: Roche Investor Update - August 31, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome
Roche announced today that the US Food and Drug Administration (FDA) has approved Actemra/RoActemra ® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in patients two years of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - August 30, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review for Roche ’s Gazyva in previously untreated follicular lymphoma
Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Gazyva® (obinutuzumab) in combination with chemotherapy followed by Gazyva alone for people with previously untreated follicular lymphoma, one of the most common blood cancers among adults. Follicular lymphoma, a slow-growing (indolent) form of non-Hodgkin lymphoma, is incurable and characterized by cycles of remission and relapse. (Source: Roche Investor Update)
Source: Roche Investor Update - August 28, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review to Roche ’s emicizumab for haemophilia A with inhibitors
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA) and granted Priority Review for emicizumab prophylaxis (preventative) as a once-weekly subcutaneous treatment for adults, adolescents and children with haemophilia A with factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - August 24, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s Alecensa Priority Review for initial treatment of people with ALK-positive lung cancer
Roche announced today that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental New Drug Application (sNDA) and granted Priority Review for Alecensa® (alectinib) as an initial (first-line) treatment for people with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Source: Roche Investor Update)
Source: Roche Investor Update - August 3, 2017 Category: Pharmaceuticals Source Type: news

FDA grants breakthrough therapy designation for Venclexta in acute myeloid leukaemia
Roche today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Venclexta ® (venetoclax) in combination with low dose cytarabine (LDAC) for elderly patients with previously untreated AML who are ineligible for intensive chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - July 28, 2017 Category: Pharmaceuticals Source Type: news

Roche reports strong performance in the first half of 2017
Group sales increase 5% at constant exchange rates and in Swiss francs (Source: Roche Investor Update)
Source: Roche Investor Update - July 27, 2017 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2017
We are pleased to invite you to an analyst event on Tuesday, 1st August 2017 to discuss Roche ’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in San Diego, California (July 30-August 3, 2017). (Source: Roche Investor Update)
Source: Roche Investor Update - July 25, 2017 Category: Pharmaceuticals Source Type: news

Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. (Source: Roche Investor Update)
Source: Roche Investor Update - July 21, 2017 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Gazyvaro for people with previously untreated advanced follicular lymphoma
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro ® (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people achieving a response, as a new treatment option for previously untreated advanced follicular lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - July 21, 2017 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval for Roche ’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for TECENTRIQ ® (atezolizumab) as a monotherapy for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - July 21, 2017 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2017
We are pleased to invite you to an analyst event on Tuesday, 1st August 2017 to discuss Roche ’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in San Diego, California (July 30-August 3, 2017). (Source: Roche Investor Update)
Source: Roche Investor Update - July 18, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia
Roche announced today that OCREVUS ® (ocrelizumab) has been approved by the Australian Therapeutic Goods Administration (TGA) for the treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), marking the second approval of OCREVUS for both indications following the FDA decision in th e US in March 2017. (Source: Roche Investor Update)
Source: Roche Investor Update - July 17, 2017 Category: Pharmaceuticals Source Type: news

Positive phase III results for Roche ’s emicizumab in haemophilia A published in The New England Journal of Medicine
Roche today announced that data from HAVEN 1, a phase III study evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and adolescents with haemophilia A with inhibitors, were published in The New England Journal of Medicine (NEJM). (Source: Roche Investor Update)
Source: Roche Investor Update - July 10, 2017 Category: Pharmaceuticals Source Type: news

Invitation to Roche Analyst Event at ISTH 2017
We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Haemostasis Congress (ISTH) in Berlin 8 – 13 July 2017. (Source: Roche Investor Update)
Source: Roche Investor Update - July 7, 2017 Category: Pharmaceuticals Source Type: news

Invitation to Roche Analyst Event on Diagnostics Division at AACC 2017
We are pleased to invite you to an analyst event on Tuesday, 1st August 2017 to discuss Roche ’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in San Diego, California (July 30-August 3, 2017). (Source: Roche Investor Update)
Source: Roche Investor Update - July 4, 2017 Category: Pharmaceuticals Source Type: news

Roche expands cobas Liat PCR System menu with launch of cobas MRSA/SA test to target healthcare-associated infections
Roche announced today the CE-IVD launch of the cobas ® MRSA/SA nucleic acid test for use on the cobas® Liat® System for the qualitative detection and differentiation of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) at the point of care. MRSA and SA are both major sources of healthcare and community associated inf ections. (Source: Roche Investor Update)
Source: Roche Investor Update - July 3, 2017 Category: Pharmaceuticals Source Type: news

Reminder: Roche Analyst Event at ISTH 2017
We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Haemostasis Congress (ISTH) in Berlin 8 – 13 July 2017. (Source: Roche Investor Update)
Source: Roche Investor Update - June 30, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational medicine polatuzumab vedotin in combination with MabThera® (rituximab) and bendamustine for the treatment of people with relapsed or refractory diffuse large B cell lymphoma (DLBCL), the most common aggressive form of non-Hodgkin lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - June 30, 2017 Category: Pharmaceuticals Source Type: news

Invitation to Roche's Half Year Results 2017, Thursday 27th July 2017 - Live video webcast and conference call
Roche will publish its Half Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 27th July 2017. (Source: Roche Investor Update)
Source: Roche Investor Update - June 27, 2017 Category: Pharmaceuticals Source Type: news

Fewer pills, more flexibility in dosing: Roche ’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)
Roche today announced that the European Commission (EC) has approved a new tablet formulation of Esbriet ® (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a fatal condition that causes irreversible, progressive scarring of the lungs. (Source: Roche Investor Update)
Source: Roche Investor Update - June 27, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors
Roche today announced positive data from the primary analysis of the phase III HAVEN 1 study in adults and adolescents and interim analysis of the phase III HAVEN 2 study in children evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) for the treatment of haemophilia A with inhibitors to factor VIII. (Source: Roche Investor Update)
Source: Roche Investor Update - June 26, 2017 Category: Pharmaceuticals Source Type: news

Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Roche today announced new data from multiple studies of Venclexta ®/Venclyxto® (venetoclax), presented at the 22nd European Hematology Association (EHA) Annual Congress, 22-25 June, in Madrid. (Source: Roche Investor Update)
Source: Roche Investor Update - June 23, 2017 Category: Pharmaceuticals Source Type: news

Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma
Roche announced today that new data from additional analyses of the pivotal phase III GALLIUM study in people with previously untreated follicular lymphoma will be presented at the 22nd European Hematology Association (EHA) annual congress, 22-25 June, in Madrid, Spain. (Source: Roche Investor Update)
Source: Roche Investor Update - June 23, 2017 Category: Pharmaceuticals Source Type: news

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis
Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme in people with relapsing and primary progressive forms of multiple sclerosis (RMS and PPMS) will be presented at the 3rd Congress of the European Academy of Neurology (EAN) from 24 June to 27 June in Amsterdam, Netherlands. (Source: Roche Investor Update)
Source: Roche Investor Update - June 23, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela ™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - June 23, 2017 Category: Pharmaceuticals Source Type: news

Save the date: Roche Analyst Event on Diagnostics Division at AACC 2017
We are pleased to invite you to an analyst event on Tuesday, 1st August 2017 to discuss Roche ’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in San Diego, California (July 30-August 3, 2017). (Source: Roche Investor Update)
Source: Roche Investor Update - June 6, 2017 Category: Pharmaceuticals Source Type: news

Phase III study showed Roche ’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
Roche today announced that the phase III ALEX study showed Alecensa ® (alectinib) significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by more than half (53%) compared to crizotinib when given as initial (first-line) treatment for people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCL C) (hazard ratio (HR)=0.47, 95% CI: 0.34-0.65, p (Source: Roche Investor Update)
Source: Roche Investor Update - June 5, 2017 Category: Pharmaceuticals Source Type: news

APHINITY study shows Roche ’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer
Roche, the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced the Phase III APHINITY study showed adjuvant (after surgery) treatment with the combination of Perjeta ® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) significantly reduced the risk of breast cancer recurrence or death (invasive disease-free survival; iDFS) by 19% in people with HER2-positive early breast cancer (eBC) compared to Herceptin and chemotherapy alon e (HR=0.81; 95% CI 0.66-1.00, p=0.045). (Source: Roche Investor Update)
Source: Roche Investor Update - June 5, 2017 Category: Pharmaceuticals Source Type: news

Roche presents new data for TECENTRIQ ® (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017
Roche today announced that new data for TECENTRIQ and updates from across its extensive cancer immunotherapy clinical development programme will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting on 2 June – 6 June in Chicago, Illinois, United States. (Source: Roche Investor Update)
Source: Roche Investor Update - June 3, 2017 Category: Pharmaceuticals Source Type: news